Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Feb 2023 |
| Genmab Files Annual Report with the U.S. Securities and Exchange Commission | 22 Feb 2023 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 22 Feb 2023 |
| Genmab A/S has published its Articles of Association | 30 Jan 2023 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022 | 24 Jan 2023 |